Brief: Design Therapeutics Highlights Pipeline Progress And Reports Q4 And Full Year 2022 Financial Results

Design Therapeutics

14/03/2023 21:38

March 14 (Reuters) - Design Therapeutics Inc  DSGN.O :
    * DESIGN THERAPEUTICS HIGHLIGHTS PIPELINE PROGRESS AND
REPORTS
FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS
    * PHASE 1 MULTIPLE-ASCENDING DOSE TRIAL OF DT-216 FOR
FRIEDREICH
ATAXIA ONGOING WITH DATA EXPECTED MID-YEAR
    * DESIGN THERAPEUTICS-CONTINUED PROGRESS ACROSS PIPELINE OF
GENETAC SMALL MOLECULES WITH 3 PROGRAMS EXPECTED TO BE IN
CLINICAL DEVELOPMENT IN NEXT 2 YEARS
    * STRONG FINANCIAL POSITION WITH $330 MILLION IN CASH AND
SECURITIES EXPECTED TO SUPPORT OPERATING RUNWAY THROUGH 2025
    * QTRLY LOSS PER SHARE $0.31
    * Q4 EARNINGS PER SHARE VIEW $-0.34 -- REFINITIV IBES DATA

Source text for Eikon:  ID:nGNXc54Yrf 
Further company coverage:  DSGN.O 

 ((Reuters.Briefs@thomsonreuters.com;))